Adjuvant intravesical therapy for superficial bladder cancer

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Superficial bladder cancer requires effective adjuvant intravesical therapies to prevent recurrence and progression.
• Intravesical instillation of agents like thiotepa, mitomycin, doxorubicin, and Bacillus Calmette-Guérin (BCG) vaccine is a common treatment strategy.

Purpose of the Study:

• To review clinical trial outcomes and adverse drug effects of thiotepa, mitomycin, doxorubicin, and BCG vaccine as adjuvant intravesical therapy for superficial bladder cancer.
• To compare the efficacy and safety profiles of these agents in preventing tumor recurrence and progression.

Main Methods:

• A MEDLINE search of English-language literature was conducted using terms related to bladder neoplasms and the specific intravesical agents.
• Data from human and in vitro studies were assessed, focusing on clinical trials evaluating dosage, regimens, and therapeutic response.
• Comparative data strength and therapeutic response were key evaluation criteria.

Main Results:

• Adjuvant intravesical therapy with doxorubicin, thiotepa, BCG, and mitomycin is effective in superficial bladder cancer, offering better protection against recurrence than transurethral resection alone.
• These therapies can prolong the time before cystectomy is required.

Conclusions:

• Randomized clinical trials indicate Bacillus Calmette-Guérin (BCG) vaccine is more effective than thiotepa, doxorubicin, and mitomycin in preventing bladder tumor recurrence and progression.
• All four agents can cause local cystitis; BCG vaccine is associated with a higher incidence of adverse reactions like dysuria and hematuria, and occasionally flu-like symptoms, though severe effects are rare at recommended doses.